Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Medivir AB (publ)
  6. News
  7. Summary
    MVIR B   SE0000273294


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Medivir : Phase II COSMOS study results published in The Lancet on World Hepatitis Day

07/28/2014 | 05:24am EDT

Press release as PDF

Phase II COSMOS study results published in The Lancet on World Hepatitis Day

Stockholm, Sweden - Medivir AB (OMX: MVIR) announces that results from the phase II COSMOS clinical study were published July 28 in The Lancet, demonstrating that 92 percent of genotype 1 chronic hepatitis C virus adult patients treated with simeprevir in combination with sofosbuvir achieved sustained virologic response 12 weeks after the end of treatment (SVR12). The study included patients with compensated cirrhosis and prior null response to treatment with pegylated interferon and ribavirin.

According to results from the study, the all-oral, interferon-free treatment regimen with simeprevir and sofosbuvir resulted in consistent SVR12 rates regardless of degree of fibrosis, and was an effective and well-tolerated therapeutic regimen in both treatment-naïve and prior null-responder patients.

"The Lancet publication of the COSMOS data on World Hepatitis Day gives further recognition to these revolutionizing treatment results. I hope that this will contribute to helping more patients around the world to get cured." says Henrik Krook, EVP Commercial, Medivir AB.

Based on the findings from the COSMOS study, our partner Janssen in April initiated the phase III studies OPTIMIST-1 and OPTIMIST-2 examining the safety and efficacy of simeprevir and sofosbuvir without interferon or ribavirin for the treatment of chronic genotype 1 hepatitis C infection.

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292

About Simeprevir (Olysio®)
Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen. Simeprevir efficacy has been established in HCV genotype 1 and HCV genotype 4 infected patients with compensated liver disease, including cirrhosis.

Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. Simeprevir was approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis. Simeprevir was approved in September 2013 in Japan, in November 2013 in Canada and the U.S., in March 2014 in Russia and in July 2014 in Mexico and Australia.

In May 2014 simeprevir was granted marketing authorization by the European Commission (EC) for the treatment of adult patients with genotype 1 or genotype 4 chronic HCV. Following the EMA approval, it is anticipated that simeprevir will be available across a number of European Union countries in conjunction with reimbursement, in the second half of 2014. Simeprevir (Olysio) is marketed under the trade name Sovriad® in Japan and Russia, Galexos™ in Canada and Olysio® in the U.S. and European Union.

About Medivir
Medivir is an emerging and profitable research-based pharmaceutical company with an established marketing and sales organisation in the Nordics with a broad portfolio of prescription pharmaceuticals. Medivir receives royalty from Johnson & Johnson global sales of the hepatitis C pharmaceutical Olysio. In addition, revenues for sales of Olysio in the Nordic region is generated through the companies own sales and marketing organisation.  

Medivir's research and development portfolio of pharmaceuticals is based on the company's expertise in polymerase and protease drug targets for different disease areas. The company's current research and development is focused on infectious diseases, bone related disorders, neuropathic pain and oncology.

Medivir is listed on the Nasdaq OMX Mid-Cap list.

distributed by

© Publicnow 2014
All news about MEDIVIR AB (PUBL)
09/16MEDIVIR : invites to a conference call on new clinical data and further studies ..
09/16Medivir AB Ipresents New Clinical Data and Further Studies with MIV-818 At Eu..
09/13MEDIVIR : Presentation
09/13MEDIVIR : Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published
09/13Medivir AB Announces Abstract for MIV-818 phase 1b monotherapy for ESMO Congr..
09/10MEDIVIR : to present at the Wainwright Annual Global Investment Conference
08/31MEDIVIR : receives regulatory approval from MHRA for phase 1/2a combination stud..
08/31Medivir AB Receives Regulatory Approval from MHRA for Phase 1/2A Combination ..
08/19MEDIVIR : Interim Report January-June 2021.pdf
08/19MEDIVIR : Interim report january - june 2021
More news
Sales 2021 34,0 M 3,92 M 3,92 M
Net income 2021 -129 M -14,8 M -14,8 M
Net Debt 2021 83,0 M 9,56 M 9,56 M
P/E ratio 2021 -2,18x
Yield 2021 -
Capitalization 573 M 66,0 M 66,0 M
EV / Sales 2021 19,3x
EV / Sales 2022 34,3x
Nbr of Employees 8
Free-Float 76,1%
Duration : Period :
Medivir AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDIVIR AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 10,28 SEK
Average target price 26,00 SEK
Spread / Average Target 153%
EPS Revisions
Managers and Directors
Magnus Christensen Chief Executive & Financial Officer
Uli Alf Hacksell Chairman
Fredrik Öberg Chief Scientific Officer
Tom Morris Chief Medical Officer
Christina Elisabeth Herder Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350